Related by context. All words. (Click for frequent words.) 76 assessing T DM1 73 metastatic renal cell 72 Pemetrexed 72 mRCC 72 relapsed MM 72 FOLFOX6 72 relapsed refractory multiple myeloma 72 platinum refractory 72 CIMZIA ™ 71 gemcitabine carboplatin 71 carboplatin paclitaxel 71 relapsed multiple myeloma 71 FOLFOX regimen 71 ribavirin RBV 70 VELCADE melphalan 70 metastatic GIST 70 CIMZIA TM 70 Amrubicin 70 CHOP chemotherapy 70 recurrent NSCLC 70 MAGE A3 ASCI 70 ZACTIMA 70 HER2 positive metastatic breast 70 oral ridaforolimus 70 metastatic CRPC 69 gemcitabine chemotherapy 69 systemic ALCL 69 Doxil ® 69 SCCHN 69 FOLFOX4 69 docetaxel chemotherapy 69 FIRMAGON 69 lenalidomide Revlimid R 69 HRPC 69 Hycamtin ® 69 metastatic HRPC 69 dacarbazine 69 Traficet EN 69 docetaxel Taxotere R 69 FOLFIRI 68 pegfilgrastim 68 metastatic hormone refractory 68 Aflibercept 68 sunitinib malate 68 pertuzumab 68 dasatinib Sprycel ® 68 forodesine 68 Pegasys ® 68 elotuzumab 68 metastatic renal cell carcinoma 68 Fludara 68 pegylated interferon alpha 68 regorafenib 68 lumiliximab 68 LEUKINE 68 Metastatic Colorectal Cancer 68 Troxatyl 68 docetaxel Taxotere ® 68 KRAS mutations occur 68 mCRC 68 OncoVEX GM CSF 68 refractory multiple myeloma 68 pegylated liposomal doxorubicin 68 melphalan prednisone 68 anthracycline taxane 68 ganetespib 68 cetuximab Erbitux ® 68 recurrent GBM 68 plus gemcitabine 68 oblimersen 68 bevacizumab Avastin ® 68 mCRC patients 68 Trastuzumab 68 CANCIDAS 68 CIMZIA TM certolizumab pegol 68 low dose cytarabine 68 KRAS wild 68 chlorambucil 68 plus dexamethasone 68 Taxotere ® 68 thalidomide Thalomid 67 TTF Therapy 67 Aloxi injection 67 lintuzumab SGN 67 docetaxel Taxotere 67 crizotinib PF # 67 capecitabine Xeloda 67 Bezielle 67 elacytarabine 67 Alocrest 67 alvespimycin 67 anthracyclines taxanes 67 TORISEL 67 IMA# 67 OZURDEX ® 67 tyrosine kinase inhibitor TKI 67 5 fluorouracil leucovorin 67 complete cytogenetic response 67 alfa 2a 67 unresectable locally advanced 67 acyclovir Lauriad R 67 phase IIb clinical 67 TELCYTA 67 erlotinib Tarceva ® 67 SPRYCEL ® 67 colorectal cancer liver metastases 67 Targretin capsules 67 Hormone Refractory Prostate Cancer 67 dose cohort 67 postoperative chemotherapy 67 TYKERB 67 ALGRX 67 refractory AML 67 taxane chemotherapy 67 heavily pretreated patients 67 interferon ribavirin 67 Tarceva TM 67 EOquin TM 67 ELACYT 67 achieved CCyR 67 HBeAg positive patients 67 carboplatin chemotherapy 67 estramustine 67 recurrent glioblastoma multiforme 67 neoadjuvant treatment 67 PegIFN RBV 67 gemcitabine cisplatin 67 refractory metastatic colorectal cancer 67 interferon beta therapy 67 Pegasys plus Copegus 67 stage IIIb IV 67 galiximab 67 pegylated interferon alfa 67 IRX 2 67 refractory chronic lymphocytic 67 PSMA ADC 67 glufosfamide 67 evaluating tivozanib 67 bortezomib Velcade R 66 hA# 66 refractory NSCLC 66 refractory metastatic 66 non squamous NSCLC 66 budesonide foam 66 BRIM2 66 evaluating T DM1 66 FOLFOX chemotherapy 66 Fludarabine 66 receptor tyrosine kinase inhibitor 66 gemcitabine Gemzar 66 Tarceva erlotinib 66 gastrointestinal stromal tumor GIST 66 Fludara ® 66 metastatic colorectal cancer 66 Phase #b/#a clinical 66 dacarbazine DTIC 66 infusional 5-FU/LV 66 alkylating agent 66 PEGINTRON TM 66 immunotherapeutic agent 66 imatinib Gleevec ® 66 CAELYX 66 AVASTIN 66 fluoropyrimidine 66 SUTENT 66 adalimumab Humira 66 FOLFIRI chemotherapy 66 dasatinib Sprycel 66 Gleevec imatinib mesylate 66 catheter occlusion 66 paclitaxel carboplatin 66 nab paclitaxel 66 Omacetaxine 66 multiple myeloma MM 66 briakinumab 66 decitabine 66 CCX# 66 adecatumumab 66 bendamustine 66 Irinotecan 66 leukemia AML 66 Dacogen decitabine 66 AMEVIVE 66 liposomal doxorubicin 66 Natalizumab 66 Quinamed 66 gastrointestinal stromal tumors GIST 66 Phase IIIb clinical 66 Gliadel Wafer 66 FluCAM 66 plus prednisone 66 resminostat 66 docetaxel prednisone 66 CYT# potent vascular disrupting 66 standard chemotherapy regimen 66 sipuleucel T 66 cetuximab Erbitux R 66 certolizumab 66 GW# [003] 66 MCyR 66 advanced unresectable 66 prostate cancer HRPC 66 Ixempra 66 metastatic malignant melanoma 66 IRESSA 66 pomalidomide 66 mycophenolate mofetil 66 FOLPI 66 metastatic malignant 65 MabCampath 65 imetelstat 65 CRp 65 imatinib mesylate Gleevec 65 ritonavir boosted 65 ribavirin therapy 65 pegylated interferon alfa 2a 65 mg/m2 dose 65 IV NSCLC 65 peginterferon alfa 65 chemoradiation therapy 65 trastuzumab Herceptin 65 Folfox 65 EGFR TKI 65 Gemzar ® 65 temsirolimus Torisel ® 65 anthracycline containing 65 vinca alkaloid 65 Panzem R NCD 65 DOXIL 65 Copegus ribavirin 65 partial remissions 65 telaprevir dosed 65 paclitaxel Taxol ® 65 PI3K/Akt pathway inhibitor 65 axitinib 65 concurrent chemoradiation 65 Genasense ® 65 paclitaxel Taxol 65 Brentuximab Vedotin SGN 65 remission CR 65 nilotinib 65 Neulasta ® 65 Ophena TM 65 ongoing Phase 1b 65 trabectedin 65 ixabepilone 65 pain palliation 65 superficial bladder cancer 65 sargramostim 65 Ozarelix 65 CR# vcMMAE 65 HuMax EGFr 65 YONDELIS 65 acute GvHD 65 HuMax CD4 65 Phase Ib study 65 relapsed SCLC 65 vidofludimus 65 HCV RESPOND 2 65 INC# 65 ACTEMRA TM 65 Xelox 65 Gleevec Glivec 65 bevacizumab Avastin 65 tanespimycin 65 unresectable stage 65 Ceplene/IL-2 65 BEXXAR 65 Camptosar ® 65 Follicular Lymphoma 65 romidepsin 65 liposomal formulation 65 APTIVUS r 65 EGFR expressing mCRC 65 Pertuzumab 65 oral allopurinol 65 doxorubicin docetaxel 65 dosing cohort 65 #mg BID [001] 65 NeuroStar TMS Therapy 65 sorafenib Nexavar 65 phase IIb trial 65 rilonacept 65 resectable pancreatic cancer 65 ofatumumab 65 metaglidasen 65 orally administered inhibitor 65 ZOLINZA 65 R sorafenib tablets 65 Phase 2a trial 65 5-FU/LV 65 epirubicin cyclophosphamide 65 novel VDA molecule 65 G#DT 65 boosted protease inhibitor 65 naïve HCV 65 MYDICAR ® 65 adriamycin 65 tumors GIST 65 mitoxantrone plus 65 radiation sensitizer 65 Xanafide 65 achieved ACR# 65 oral clodronate 65 cell lymphoma CTCL 65 tipranavir 65 rFVIIa 65 CTAP# Capsules 65 metastatic RCC 65 biliary tract cancer 65 custirsen 65 goserelin 65 heavily pretreated 65 Dacogen injection 65 Aptivus ® 65 zalutumumab 65 recurrent glioblastoma 65 CR nPR 65 MabThera Rituxan 65 tenofovir emtricitabine 65 BRAF inhibitor 65 Q#IR 65 evaluating Xcytrin 65 SNT MC# 65 cisplatin vinorelbine 65 PANVAC VF 65 chemotherapy cisplatin 65 metastatic colorectal carcinoma 65 idarubicin 65 advanced NSCLC 65 CD3 monoclonal antibody 65 SinuNase TM 64 fallopian tube carcinoma 64 Proxinium TM 64 INCB# [001] 64 PEG SN# 64 TAXOTERE R 64 ARB telmisartan 64 BR.# 64 interferon alfa 2a 64 aflibercept VEGF Trap 64 Allovectin 7 64 lymphoma CTCL 64 DCVax ® Brain 64 comparator arm 64 hormone refractory prostate cancer 64 interferon gamma 1b 64 #mg/m# [001] 64 Platinol ® 64 unresectable 64 virologic failure 64 indolent NHL 64 bortezomib refractory 64 AGILECT R 64 PEG interferon 64 hepatocellular cancer 64 Xcellerated T Cells 64 dose cytarabine 64 trastuzumab Herceptin R 64 biologic DMARD 64 CLL SLL 64 Targretin 64 letrozole Femara 64 SVR# 64 Pegylated Interferon 64 XELOX 64 ORENCIA ® 64 chemoradiotherapy 64 Glufosfamide 64 relapsing multiple sclerosis 64 evaluable subjects 64 recurrent metastatic 64 dose cohorts 64 Allovectin 7 ® 64 FOLFOX 64 cytogenetic response 64 LymphoStat B belimumab 64 HGS# 64 Aplidin 64 PASI scores 64 phase IIb study 64 PEG IFN 64 Cimzia TM 64 Xeloda ® 64 sorafenib tablets 64 vinorelbine 64 PRT# 64 ponatinib 64 Bevacizumab 64 paclitaxel Taxol R 64 relapsed CLL 64 TKI therapy 64 cilengitide 64 alpha folate receptor 64 cediranib 64 placebo dexamethasone 64 CLARITY study 64 amoxicillin clavulanate 64 FOLFIRI alone 64 alemtuzumab Campath 64 trastuzumab Herceptin ® 64 metastatic colorectal 64 AEG# 64 mapatumumab 64 Taxotere R 64 HCD# [002] 64 DEB# 64 Raptiva r 64 chemotherapy gemcitabine 64 Erlotinib 64 AZT zidovudine Retrovir 64 APTIVUS R 64 novel histone deacetylase 64 3 registrational trial 64 relapsing remitting MS RRMS 64 mitomycin 64 Imprime PGG 64 PDX pralatrexate 64 paclitaxel cisplatin 64 cisplatin gemcitabine 64 5 FU leucovorin 64 systemic anaplastic large 64 PegIFN 64 Phase #/#a trial 64 FOLFOX6 chemotherapy regimen 64 Peginterferon alfa 2b 64 ara C 64 MKC# MT 64 protease inhibitor PI 64 ofatumumab HuMax CD# 64 MGd 64 refractory CTCL 64 cetuximab Erbitux 64 pemetrexed Alimta 64 Raptiva ® 64 Seliciclib 64 rALLy 64 advanced nonsquamous NSCLC 64 metastatic castration resistant 64 prospectively stratified 64 phase IIa clinical 64 HBeAg seroconversion 64 CVP chemotherapy 64 including eniluracil ADH 64 REYATAZ R 64 ASCT 64 doublet chemotherapy 64 Metastatic Melanoma 64 Advanced Renal Cell 64 follicular lymphoma FL 64 pemetrexed 64 vincristine doxorubicin 64 non metastatic osteosarcoma 64 registrational trial 64 gefitinib Iressa 64 Elitek 64 Peg IFN 64 intravesical infusion therapy 64 pegylated interferon alpha 2a 64 Navelbine ® 64 Tavocept 64 IV Busulfex 64 neoadjuvant chemotherapy 64 FASLODEX 64 posaconazole 64 clodronate 64 miconazole Lauriad ® 64 docetaxel 64 Chemophase 64 ARIMIDEX 64 Nanobody 64 temsirolimus 64 Golimumab 64 Dasatinib 64 docetaxel Injection Concentrate 64 sorafenib Nexavar ® 64 CCX# B 64 refractory gout 64 HGS ETR1 64 TEMODAL 64 mcg albinterferon alfa 2b 64 cisplatin chemotherapy 64 Cloretazine ® 63 PROMACTA 63 Besivance 63 oral vancomycin 63 azacitidine 63 OvaRex ® MAb 63 Ceflatonin 63 Clolar ® 63 Gleevec imatinib 63 ELOXATIN 63 seliciclib 63 Renal Cell Carcinoma RCC 63 thymalfasin 63 HBeAg negative patients 63 dose escalation phase 63 treatment naïve genotype 63 Hepatocellular Carcinoma HCC 63 metastatic castrate resistant 63 mTOR inhibitor 63 reslizumab 63 Epratuzumab 63 BCIRG 63 Vidaza R 63 verteporfin 63 somatostatin analog 63 PREZISTA r 63 recurrent genital herpes 63 brivaracetam 63 omacetaxine mepesuccinate 63 brentuximab vedotin SGN 63 baminercept 63 Telatinib 63 Azedra 63 R# #mg BID 63 Virulizin ® 63 vandetanib 63 undetectable HCV RNA 63 KRAS status 63 non squamous 63 BARACLUDE ® 63 MYCAMINE 63 FOLOTYN 63 EGFR expressing 63 ribavirin Copegus ® 63 Vicinium TM 63 herpetic keratitis 63 histone deacetylase HDAC inhibitor 63 PEGylated Fab fragment 63 Pivotal Phase III 63 LUX Lung 63 mg kg dose 63 nilotinib Tasigna ® 63 hormone refractory metastatic prostate 63 neoadjuvant 63 hylan GF 63 Vfend 63 oxaliplatin Eloxatin 63 Arimidex anastrozole 63 pegylated interferon peg IFN 63 rindopepimut 63 XIENCE V stent 63 trial evaluating Prochymal 63 BRIM3 63 biologic therapy 63 iniparib 63 Tesetaxel 63 Zevalin R Ibritumomab 63 PRECiSE 63 dexamethasone Decadron 63 mg/m2 cohort 63 rALLy clinical trial 63 HQK 63 refractory cutaneous T 63 Pivotal Phase 63 E1 INT TM 63 Torisel 63 Pegasys peginterferon alfa 2a 63 OMNARIS Nasal Spray 63 Tiuxetan 63 4mg/kg 63 GEM OS1 63 opioid induced constipation OIC 63 Nexavar ® 63 achieved PASI 63 EFAPROXYN 63 trabedersen 63 pegylated liposomal doxorubicin PLD 63 Peginterferon 63 Cloretazine 63 sunitinib Sutent ® 63 q#d 63 Vandetanib 63 RAPTIVA 63 advanced hepatocellular carcinoma 63 amrubicin 63 inhaled treprostinil 63 infliximab monotherapy 63 B CLL 63 Betaferon R 63 VNP#M 63 Oxaliplatin 63 refractory Hodgkin lymphoma 63 dermaPACE TM 63 evaluating picoplatin 63 VALSTAR 63 EGFR HER2 63 debulking surgery 63 obatoclax 63 fluticasone salmeterol 63 Paraplatin ® 63 nucleoside analog 63 recurrent malignant glioma 63 ACZ# 63 vinorelbine tartrate 63 relapsed ovarian cancer 63 eosinophilic asthma 63 mertansine 63 delivers fluocinolone acetonide FA 63 relapsed Hodgkin lymphoma 63 UPLYSO 63 Zorbtive TM 63 Eloxatin ® 63 Vidaza ® 63 Velcade bortezomib 63 CBLC# 63 oxymorphone ER 63 PNP inhibitor 63 TRISENOX ® 63 talactoferrin 63 imatinib therapy 63 CIPN 63 Paraplatin ® carboplatin 63 depsipeptide 63 deforolimus 63 PROSTVAC ® 63 dacarbazine chemotherapy 63 Boceprevir 63 randomized controlled Phase 63 Taxol ® 63 irinotecan chemotherapy 63 chemotherapeutic regimen 63 TroVax ® 63 metastatic SCCHN 63 oral chemotherapeutic agent 63 invasive candidiasis 63 Increlex ® 63 Ceflatonin ® 63 follicular NHL 63 previously untreated follicular 63 TLK# 63 nucleotide analog 63 invasive aspergillosis 63 5 Fluorouracil 63 Surgical resection 63 Neupogen ® 63 hypereosinophilic syndrome 63 stage IIIB 63 adjuvant radiation 63 teriflunomide 63 ARCALYST ® rilonacept 63 Loramyc R 63 complete cytogenetic 63 indolent follicular non 63 Alkeran 63 undetectable HBV DNA 63 esophageal candidiasis 63 Phase IIa trials 63 myelodysplastic myeloproliferative diseases 63 MyVax R 63 randomized Phase IIb 63 BCG refractory 63 bortezomib Velcade 63 Rebif ® 63 sunitinib 63 abiraterone acetate 63 CoFactor 63 pamidronate 63 LymphoStat B TM 63 DAPT 63 trastuzumab DM1 T DM1 63 lymphoid malignancies 63 folinic acid 63 Augment Injectable 63 Ceflatonin R 63 Albuferon TM 63 Cetuximab Erbitux 63 ChronVac C ® 63 resistant ovarian cancer 63 Jevtana 63 dexanabinol 63 basal insulins 63 OMAPRO 63 INCB# [003] 63 beta 1a 63 ISENTRESS 63 lexidronam injection 63 cyclophosphamide methotrexate 63 saline placebo 63 BEXXAR Therapeutic Regimen 63 GAMMAGARD 62 EndoTAGTM 1 62 EndoTAG TM -1 62 cytoreduction 62 IMiD 62 BAY #-# 62 Kepivance 62 xanthine oxidase inhibitor 62 Lenocta 62 CCyR 62 XYOTAX TM 62 cutaneous T cell 62 ALT flares 62 salmeterol fluticasone 62 5-fluorouracil/leucovorin 62 PXD# 62 Pegylated Liposomal Doxorubicin 62 IFN α 62 underwent resection 62 Azilect ® 62 daunorubicin 62 mg TID 62 FUSILEV enhances 62 chemotherapy regimens 62 eltrombopag 62 Sprycel dasatinib 62 castration resistant prostate cancer 62 genotypic resistance 62 CYPHER Stent 62 recurrent glioma 62 mcg QD 62 metastatic carcinoma 62 LHRH analogues 62 elagolix 62 resectable 62 NovoTTF 62 alemtuzumab treated 62 Randomized Phase 62 Phase Ib II 62 Cimzia ® certolizumab pegol 62 cyclophosphamide chemotherapy 62 SUCCEED trial 62 Neulasta R 62 viral kinetics 62 cytotoxic therapy 62 enzastaurin 62 GetGoal Phase III 62 XIENCE V PROMUS Stent 62 Vascugel ® 62 huN# DM1 62 Infusion reactions 62 HSCT 62 prednisone prednisolone 62 voriconazole 62 Meets Primary Endpoint 62 oral rivaroxaban 62 Halaven 62 Annamycin 62 ONCASPAR 62 velafermin 62 PegIntron 62 calcineurin inhibitor 62 lintuzumab 62 biochemical relapse 62 IMGN# 62 argatroban 62 unresectable liver cancer 62 Free Survival PFS 62 rFSH 62 tigecycline 62 detectable HCV RNA 62 lapatinib Tykerb 62 pimecrolimus 62 GLIADEL R Wafer 62 Betaferon ® 62 colorectal liver metastases 62 pazopanib 62 -#.# log# 62 Gastrointestinal Stromal Tumors 62 adult chronic ITP 62 dose dexamethasone 62 untreated multiple myeloma 62 Fibrin Pad 62 prospectively defined 62 VALSTAR TM 62 metastatic carcinoid 62 stage IIIb 62 EDEMA3 62 refractory ovarian cancer 62 Ophena 62 GSK# [001] 62 postmenopausal osteoporotic women 62 dasatinib 62 microbiological eradication 62 treatment naive genotype 62 retinal vein occlusion induced 62 Elagolix 62 peginterferon alfa 2a 62 Loceryl ® 62 Flu Cy 62 ErbB2 positive 62 Intravitreal 62 YERVOY 62 definite stent thrombosis 62 ThermoDox R 62 peginterferon alfa 2b 62 Xeloda capecitabine 62 8mg/kg 62 Doxorubicin 62 ospemifene 62 ritonavir boosted lopinavir 62 ONTAK 62 ANCHOR trial 62 Phase III randomized controlled 62 antibody MAb 62 Genentech Rituxan 62 etanercept Enbrel 62 azilsartan medoxomil 62 q#h 62 Degarelix 62 HER2 overexpression 62 Abbott HUMIRA 62 ON #.Na 62 Herceptin trastuzumab 62 Taxotere docetaxel 62 octreotide LAR 62 telaprevir VX 62 sustained virological response 62 tocilizumab 62 haematologic 62 Gemcitabine 62 ZEVALIN 62 HCV Genotype 62 capecitabine Xeloda R 62 Telintra 62 Engerix B 62 farletuzumab 62 virus HCV protease inhibitor 62 huC# DM4 62 prior chemotherapy regimens 62 valopicitabine 62 Nexavar sorafenib 62 Acute Myeloid Leukaemia AML 62 telomerase therapeutic 62 Kit CD# positive 62 ZYVOX 62 Platinol ® cisplatin 62 cytogenetic responses 62 samalizumab 62 anti TNF alpha 62 peginterferon alfa 2a #KD 62 plus prednisone prednisolone 62 naive HCV 62 taxotere 62 MVax R 62 AVOREN 62 tipranavir r 62 ARCALYST ® 62 metastatic pancreatic 62 Eloxatin R 62 taxane 62 neratinib 62 iniparib BSI 62 adalimumab 62 ® bortezomib 62 opioid induced bowel dysfunction 62 Cutaneous T 62 PKC# 62 μg dose 62 RhuDex ® 62 BCG refractory carcinoma 62 oral prodrug 62 sustained virologic response 62 investigational monoclonal antibody 62 multi kinase inhibitor 62 OMP #R# 62 BENICAR HCT 62 PEGylated interferon beta 1a 62 XL# SAR# 62 advanced carcinoid 62 fallopian tube cancers 62 LymphoStat B 62 immunomodulatory therapy 62 Castration Resistant Prostate Cancer 62 glatiramer acetate 62 DexaSite 62 EGFR mutation positive 62 Aplidin R 62 luteinizing hormone releasing 62 Actemra tocilizumab 62 occlusion PAO 62 ritonavir boosted atazanavir 62 VFEND 62 de novo kidney transplant 62 investigational immunotherapy 62 Acute Myelogenous Leukemia AML 62 leading oral taxane 62 autologous SCT 62 IV bolus 62 BrachySil 62 tumor xenograft models 62 chemotherapeutic regimens 62 oral Hycamtin 62 MNTX 62 virological failure 62 Tekamlo 62 cinacalcet 62 standard chemotherapy regimens 62 Virologic 62 dose melphalan 62 leukemia CLL 62 cutaneous T 62 VICTRELIS 62 octreotide implant 62 Xyfid TM 62 ALA PDT 62 tyrosine kinase inhibitor 62 tumor lysis syndrome 62 fluvastatin 62 Neoadjuvant 62 RAPAFLO 62 INTELENCE 62 Capecitabine 62 Temodar ® 62 MoxDuo IR 62 talabostat 62 irbesartan 62 ® lenalidomide 62 5FU 62 nilotinib Tasigna 62 dopamine partial agonist 62 NMIBC 62 haematologic malignancies 62 Certican 62 #mg/m# [002] 62 Lantus ® 62 Sudhir Agrawal D.Phil 62 Lenalidomide 62 complete remissions 62 basiliximab 62 Raptiva R 62 dosing cohorts 62 CA4P 62 aflibercept 62 ABVD 62 Zolinza 62 rituximab refractory 62 Etoposide 62 ZD# [001] 62 PrevOnco ™ 62 imipenem 62 fondaparinux sodium 62 ER CHOP 62 fludarabine phosphate 62 Elotuzumab 61 oral FTY# 61 mg QD 61 pancreatic carcinoma 61 PROSTVAC TM 61 ZEVALIN ® 61 STRIDE PD 61 ChronVac C R 61 SCH # 61 ethambutol 61 tolvaptan 61 brand ciclesonide HFA 61 INTEGRILIN 61 chronic angina 61 GRN# 61 ARCOXIA 61 nalbuphine ER 61 Actimmune ® 61 angiographic outcomes 61 OMP #M# 61 adjuvant cisplatin 61 azacytidine 61 basal cell carcinoma BCC 61 satraplatin Phase 61 ® cetuximab 61 trans retinoic acid ATRA 61 protease inhibitors PIs 61 allogeneic stem cell 61 cEVR 61 Vidaza azacitidine 61 REMICADE ® 61 underwent surgical resection 61 caspofungin 61 abacavir lamivudine 61 pegylated alpha interferon 61 squamous histology 61 TMC# r 61 patients evaluable 61 Diovan HCT 61 MYLOTARG 61 NSCLC 61 malignant pleural mesothelioma 61 carotid endarterectomy CEA 61 metastatic sarcomas 61 Median progression 61 carcinoma HCC 61 gemtuzumab ozogamicin 61 curative resection 61 FROVA 61 ILUVIEN ® 61 paclitaxel chemotherapy 61 pegylated interferon alfa 2b 61 Taxol paclitaxel 61 idraparinux 61 evaluable patients 61 MoxDuo TM IR 61 oxycodone CR 61 alefacept 61 taxane therapy 61 atypical Hemolytic Uremic Syndrome 61 Ranibizumab 61 volociximab 61 phase Ib 61 CD# antibody [001]